請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26382
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 許輝吉 | |
dc.contributor.author | Su-Hsi Lue | en |
dc.contributor.author | 呂庶熙 | zh_TW |
dc.date.accessioned | 2021-06-08T07:08:17Z | - |
dc.date.copyright | 2008-09-11 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-08-01 | |
dc.identifier.citation | Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK (2003). Diffuse lymphoplasmacytic chronic cholecystitis is highly specific for extrahepatic biliary tract disease but does not distinguish between primary and secondary sclerosing cholangiopathy. Am J Surg Pathol 27, 1313-1320.
Ahn SH, Sawada H, Ro JY, Nicolson GL (1997). Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis 15, 151-156. An JY, Choi MG, Noh JH, Sohn TS, Kim S (2007). The outcome of patients with remnant primary gastric cancer compared with those having upper one-third gastric cancer. Am J Surg 194, 143-147. Bitto E, Cho W (1998). Roles of individual domains of annexin I in its vesicle binding and vesicle aggregation: a comprehensive mutagenesis study. Biochemistry 37, 10231-10237. Boige V, Laurent-Puig P, Fouchet P, Flejou JF, Monges G, Bedossa P, Bioulac-Sage P, Capron F, Schmitz A, Olschwang S, Thomas G (1997). Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 57, 1986-1990. Burgoyne RD (1988). Calpactin in exocytosis. Nature 331, 20. Caygill CP, Hill MJ, Kirkham JS, Northfield TC (1986). Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet 1, 929-931. Chang KS, Wang G, Freireich EJ, Daly M, Naylor SL, Trujillo JM, Stass SA (1992). Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood 79, 1802-1810. Chen CN, Lee WJ, Lee PH, Chang KJ, Chen KM (1996). Clinicopathologic characteristics and prognosis of gastric stump cancer. J Clin Gastroenterol 23, 251-255. Chen TC, Hsieh LL, Kuo TT, Ng KF, Wu Chou YH, Jeng LB, Chen MF (2000). p16INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma. Anticancer Res 20, 1621-1626. Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, Chiu CT, Kuo TT, Kamiya J, Oda K, Hamaguchi M, Ohno Y, Hsieh LL, Nimura Y (2001). Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 34, 651-658. Chetcuti A, Margan SH, Russell P, Mann S, Millar DS, Clark SJ, Rogers J, Handelsman DJ, Dong Q (2001). Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res 61, 6331-6334. Choi S, Kobayashi M, Wang J, Habelhah H, Okada F, Hamada J, Moriuchi T, Totsuka Y, Hosokawa M (2000). Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin. Clin Exp Metastasis 18, 45-50. Chou YH, Chung KC, Jeng LB, Chen TC, Liaw YF (1998). Frequent allelic loss on chromosomes 4q and 16q associated with human hepatocellular carcinoma in Taiwan. Cancer Lett 123, 1-6. Clark CG, Ward MW, McDonald AM, Tovey FI (1983). The incidence of gastric stump cancer. World J Surg 7, 236-240. Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52, 6735-6740. Creutz CE (1992). The annexins and exocytosis. Science 258, 924-931. Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol 12, 354-362. de Boer WA, Tytgat GN (2000). Regular review: treatment of Helicobacter pylori infection. BMJ 320, 31-34. Deloukas P, Schuler GD, Gyapay G, Beasley EM, Soderlund C, Rodriguez-Tome P, Hui L, Matise TC, McKusick KB, Beckmann JS, Bentolila S, Bihoreau M, Birren BB, Browne J, Butler A, Castle AB, Chiannilkulchai N, Clee C, Day PJ, Dehejia A, Dibling T, Drouot N, Duprat S, Fizames C, Fox S, Gelling S, Green L, Harrison P, Hocking R, Holloway E, Hunt S, Keil S, Lijnzaad P, Louis-Dit-Sully C, Ma J, Mendis A, Miller J, Morissette J, Muselet D, Nusbaum HC, Peck A, Rozen S, Simon D, Slonim DK, Staples R, Stein LD, Stewart EA, Suchard MA, Thangarajah T, Vega-Czarny N, Webber C, Wu X, Hudson J, Auffray C, Nomura N, Sikela JM, Polymeropoulos MH, James MR, Lander ES, Hudson TJ, Myers RM, Cox DR, Weissenbach J, Boguski MS, Bentley DR (1998). A physical map of 30,000 human genes. Science 282, 744-746. Dixon MF, Martin IG, Sue-Ling HM, Wyatt JI, Quirke P, Johnston D (1994). Goseki grading in gastric cancer: comparison with existing systems of grading and its reproducibility. Histopathology 25, 309-316. Eberhard DA, Karns LR, VandenBerg SR, Creutz CE (2001). Control of the nuclear-cytoplasmic partitioning of annexin II by a nuclear export signal and by p11 binding. J Cell Sci 114, 3155-3166. Emans N, Gorvel JP, Walter C, Gerke V, Kellner R, Griffiths G, Gruenberg J (1993). Annexin II is a major component of fusogenic endosomal vesicles. J Cell Biol 120, 1357-1369. Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP (2001). Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 34, 360-365. Gerke V, Moss SE (2002). Annexins: from structure to function. Physiol Rev 82, 331-371. Giuliani A, Caporale A, Demoro M, Benvenuto E, Scarpini M, Spada S, Angelico F (2005). Gastric cancer precursor lesions and Helicobacter pylori infection in patients with partial gastrectomy for peptic ulcer. World J Surg 29, 1127-1130. Goseki N, Takizawa T, Koike M (1992). Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut 33, 606-612. Gruenberg J, Emans N (1993). Annexins in membrane traffic. Trends Cell Biol 3, 224-227. Gurbuz Y, Kahlke V, Kloppel G (2002). How do gastric carcinoma classification systems relate to mucin expression patterns? An immunohistochemical analysis in a series of advanced gastric carcinomas. Virchows Arch 440, 505-511. Gurbuz Y, Kose N (2006). Cytokeratin expression patterns of gastric carcinomas according to Lauren and Goseki classification. Appl Immunohistochem Mol Morphol 14, 303-308. Hart WR (2005). Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 24, 4-25. Hattori T, Kushima R (2001). [Gastric differentiated stomach adenocarcinoma]. Pathologe 22, 97-104. Horlick KR, Ganjianpour M, Frost SC, Nick HS (1991). Annexin-I regulation in response to suckling and rat mammary cell differentiation. Endocrinology 128, 1574-1579. Kim KH, Sung CK, Park BG, Kim WG, Ryu SK, Kim KS, Paik IS, Oh CH (1998). Clinical significance of intrahepatic biliary stricture in efficacy of hepatic resection for intrahepatic stones. J Hepatobiliary Pancreat Surg 5, 303-308. Kloppel G, Kosmahl M (2006). Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm? J Hepatol 44, 249-250. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T (1996). Gastric remnant carcinoma after partial gastrectomy for benign and malignant gastric lesions. J Am Coll Surg 182, 1-6. Lauren P (1965). The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. Acta Pathol Microbiol Scand. 64, 31-49. Li H-Y (2004) Cloning and characterization of annexin A10 isoforms. Graduate Institute of Pathology, College of Medicine. National Taiwan University. Lin CY, Jeng YM, Chou HY, Hsu HC, Yuan RH, Chiang CP, Kuo MY (2008). Nuclear localization of annexin A1 is a prognostic factor in oral squamous cell carcinoma. J Surg Oncol 97, 544-550. Liu SH, Lin CY, Peng SY, Jeng YM, Pan HW, Lai PL, Liu CL, Hsu HC (2002). Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol 160, 1831-1837. Lopez-Pedrera C, Villalba JM, Siendones E, Barbarroja N, Gomez-Diaz C, Rodriguez-Ariza A, Buendia P, Torres A, Velasco F (2006). Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. Proteomics 6 Suppl 1, S293-299. Malhi H, Gores GJ (2006). Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45, 856-867. Martin IG, Dixon MF, Sue-Ling H, Axon AT, Johnston D (1994). Goseki histological grading of gastric cancer is an important predictor of outcome. Gut 35, 758-763. Masaki T, Tokuda M, Fujimura T, Ohnishi M, Tai Y, Miyamoto K, Itano T, Matsui H, Watanabe S, Sogawa K, et al. (1994). Involvement of annexin I and annexin II in hepatocyte proliferation: can annexins I and II be markers for proliferative hepatocytes? Hepatology 20, 425-435. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T, Matsui H, Arima K, Shirai M, Maeba T, Sogawa K, Konishi R, Taniguchi K, Hatanaka Y, Hatase O, Nishioka M (1996). Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 24, 72-81. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA (1999). Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340, 994-1004. Moreaux J, Mathey P, Msika S (1991). Gastric adenocarcinoma in the gastric stump after partial gastrectomy. Hepatogastroenterology 38, 517-521. Morgan RO, Bell DW, Testa JR, Fernandez MP (1999a). Human annexin 31 genetic mapping and origin. Gene 227, 33-38. Morgan RO, Jenkins NA, Gilbert DJ, Copeland NG, Balsara BR, Testa JR, Fernandez MP (1999b). Novel human and mouse annexin A10 are linked to the genome duplications during early chordate evolution. Genomics 60, 40-49. Morgan RO, Martin-Almedina S, Iglesias JM, Gonzalez-Florez MI, Fernandez MP (2004). Evolutionary perspective on annexin calcium-binding domains. Biochim Biophys Acta 1742, 133-140. Moss SE, Morgan RO (2004). The annexins. Genome Biol 5, 219. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A (1997). Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 14, 2927-2933. Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M (2003). Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 10, 265-281. Nakanuma Y, Sasaki M, Ishikawa A, Tsui W, Chen TC, Huang SF (2002). Biliary papillary neoplasm of the liver. Histol Histopathol 17, 851-861. Nakanuma Y, Tsuneyama K, Sasaki M, Harada K (2000). Destruction of bile ducts in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 14, 549-570. Nakase Y, Sakakura C, Miyagawa K, Kin S, Fukuda K, Yanagisawa A, Koide K, Morofuji N, Hosokawa Y, Shimomura K, Katsura K, Hagiwara A, Yamagishi H, Ito K, Ito Y (2005). Frequent loss of RUNX3 gene expression in remnant stomach cancer and adjacent mucosa with special reference to topography. Br J Cancer 92, 562-569. Northfield TC, Hall CN (1990). Carcinoma of the gastric stump: risks and pathogenesis. Gut 31, 1217-1219. Nygaard SJ, Haugland HK, Kristoffersen EK, Lund-Johansen M, Laerum OD, Tysnes OB (1998). Expression of annexin II in glioma cell lines and in brain tumor biopsies. J Neurooncol 38, 11-18. Offerhaus GJ, Tersmette AC, Huibregtse K, van de Stadt J, Tersmette KW, Stijnen T, Hoedemaeker PJ, Vandenbroucke JP, Tytgat GN (1988). Mortality caused by stomach cancer after remote partial gastrectomy for benign conditions: 40 years of follow up of an Amsterdam cohort of 2633 postgastrectomy patients. Gut 29, 1588-1590. Ohashi O, Yamamoto M, Ishida H, Takase S, Hasegawa K, Morita S, Kamigaki T, Saitoh Y (1995). [Retrospective analysis of postoperative chemotherapy with UFT against pancreatic cancer]. Gan To Kagaku Ryoho 22, 933-939. Ohnishi M, Tokuda M, Masaki T, Fujimura T, Tai Y, Matsui H, Itano T, Ishida T, Takahara J, Konishi R, et al. (1994). Changes in annexin I and II levels during the postnatal development of rat pancreatic islets. J Cell Sci 107 ( Pt 8), 2117-2125. Ohta T, Nagakawa T, Ueda N, Nakamura T, Akiyama T, Ueno K, Miyazaki I (1991). Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis. Cancer 68, 2217-2223. Okuda K, Nakanuma Y, Miyazaki M (2002). Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 17, 1049-1055. Orlando R, 3rd, Welch JP (1981). Carcinoma of the stomach after gastric operation. Am J Surg 141, 487-491. Paciucci R, Tora M, Diaz VM, Real FX (1998). The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene 16, 625-633. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin EF, 3rd (2000). Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 60, 6293-6297. Pencil SD, Toth M (1998). Elevated levels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma. Clin Exp Metastasis 16, 113-121. Peng SY, Ou YH, Chen WJ, Li HY, Liu SH, Pan HW, Lai PL, Jeng YM, Chen DC, Hsu HC (2005). Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol 26, 1053-1061. Pointner R, Wetscher GJ, Gadenstatter M, Bodner E, Hinder RA (1994). Gastric remnant cancer has a better prognosis than primary gastric cancer. Arch Surg 129, 615-619. Rand JH (2000). Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. J Autoimmun 15, 107-111. Rashid A, Wang JS, Qian GS, Lu BX, Hamilton SR, Groopman JD (1999). Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. Br J Cancer 80, 59-66. Raynal P, Pollard HB (1994). Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1197, 63-93. Rescher U, Gerke V (2004). Annexins - unique membrane binding proteins with diverse functions. J Cell Sci 117, 2631-2639. Roseman BJ, Bollen A, Hsu J, Lamborn K, Israel MA (1994). Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 6, 561-567. Safatle-Ribeiro AV, Ribeiro U, Jr., Reynolds JC (1998). Gastric stump cancer: what is the risk? Dig Dis 16, 159-168. Sakata T, Iwagami S, Tsuruta Y, Suzuki S, Suzuki R (1993). Study of natural lipocortin I. A potent mediator for macrophage-mediated immunosuppression in tumor-bearing mice. J Immunol 151, 4964-4972. Sarkar A, Yang P, Fan YH, Mu ZM, Hauptmann R, Adolf GR, Stass SA, Chang KS (1994). Regulation of the expression of annexin VIII in acute promyelocytic leukemia. Blood 84, 279-286. Sasako M, Maruyama K, Kinoshita T, Okabayashi K (1991). Surgical treatment of carcinoma of the gastric stump. Br J Surg 78, 822-824. Schlaepfer DD, Haigler HT (1990). Expression of annexins as a function of cellular growth state. J Cell Biol 111, 229-238. Schumacher U, Duku M, Katoh M, Jorns J, Krause WJ (2004). Histochemical similarities of mucins produced by Brunner's glands and pyloric glands: A comparative study. Anat Rec A Discov Mol Cell Evol Biol 278, 540-550. Schumacher U, Krause WJ (1995). Molecular anatomy of an endodermal gland: investigations on mucus glycoproteins and cell turnover in Brunner's glands of Didelphis virginiana using lectins and PCNA immunoreactivity. J Cell Biochem 58, 56-64. Shimonishi T, Sasaki M, Nakanuma Y (2000). Precancerous lesions of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 7, 542-550. Shiohara S, Shiozawa T, Shimizu M, Toki T, Ishii K, Nikaido T, Fujii S (1997). Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis. Cancer 80, 908-916. Silistino-Souza R, Rodrigues-Lisoni FC, Cury PM, Maniglia JV, Raposo LS, Tajara EH, Christian HC, Oliani SM (2007). Annexin 1: differential expression in tumor and mast cells in human larynx cancer. Int J Cancer 120, 2582-2589. Singh P (2007). Role of Annexin-II in GI cancers: interaction with gastrins/progastrins. Cancer Lett 252, 19-35. Smith PD, Moss SE (1994). Structural evolution of the annexin supergene family. Trends Genet 10, 241-246. Songun I, van de Velde CJ, Arends JW, Blok P, Grond AJ, Offerhaus GJ, Hermans J, van Krieken JH (1999). Classification of gastric carcinoma using the Goseki system provides prognostic information additional to TNM staging. Cancer 85, 2114-2118. Srivastava M, Bubendorf L, Nolan L, Glasman M, Leighton X, Miller G, Fehrle W, Raffeld M, Eidelman O, Kallioniemi OP, Srivastava S, Pollard HB (2001). ANX7 as a bio-marker in prostate and breast cancer progression. Dis Markers 17, 115-120. Stanley R, Lauri A, Aaltonen (2000) Pathology & Genetics - Tumours of the Digestive Systme World Health Organization Classification of Tumours, P. 37-57. Su Y, Shen J, Qian H, Ma H, Ji J, Ma L, Zhang W, Meng L, Li Z, Wu J, Jin G, Zhang J, Shou C (2007). Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci 98, 37-43. Suh KS, Roh HR, Koh YT, Lee KU, Park YH, Kim SW (2000). Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 31, 12-17. Tait JF SM, Mcmullen BA, et al. (1998). Placental anticoagulant proteins: Isolation and comparative characterization of four members of the lipocortin family. Biochemistry 27, 6268-6276. Tanigawa N, Nomura E, Niki M, Shinohara H, Nishiguchi K, Okuzawa M, Toyoda M, Morita S (2002). Clinical study to identify specific characteristics of cancer newly developed in the remnant stomach. Gastric Cancer 5, 23-28. Tatenhorst L, Rescher U, Gerke V, Paulus W (2006). Knockdown of annexin 2 decreases migration of human glioma cells in vitro. Neuropathol Appl Neurobiol 32, 271-277. Tenti P, Aguzzi A, Riva C, Usellini L, Zappatore R, Bara J, Samloff IM, Solcia E (1992). Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells. Cancer 69, 2131-2142. Theobald J, Hanby A, Patel K, Moss SE (1995). Annexin VI has tumour-suppressor activity in human A431 squamous epithelial carcinoma cells. Br J Cancer 71, 786-788. Thorban S, Bottcher K, Etter M, Roder JD, Busch R, Siewert JR (2000). Prognostic factors in gastric stump carcinoma. Ann Surg 231, 188-194. Tian MM, Zhao AL, Li ZW, Li JY (2007). Phenotypic classification of gastric signet ring cell carcinoma and its relationship with clinicopathologic parameters and prognosis. World J Gastroenterol 13, 3189-3198. Tomas A, Moss SE (2003). Calcium- and cell cycle-dependent association of annexin 11 with the nuclear envelope. J Biol Chem 278, 20210-20216. Torosyan Y, Dobi A, Naga S, Mezhevaya K, Glasman M, Norris C, Jiang G, Mueller G, Pollard H, Srivastava M (2006). Distinct Effects of Annexin A7 and p53 on Arachidonate Lipoxygenation in Prostate Cancer Cells Involve 5-Lipoxygenase Transcription. Cancer Res 66, 9609-9616. van Baal JW, Milana F, Rygiel AM, Sondermeijer CM, Spek CA, Bergman JJ, Peppelenbosch MP, Krishnadath KK (2008). A comparative analysis by SAGE of gene expression profiles of esophageal adenocarcinoma and esophageal squamous cell carcinoma. Cell Oncol 30, 63-75. Violette SM, King I, Browning JL, Pepinsky RB, Wallner BP, Sartorelli AC (1990). Role of lipocortin I in the glucocorticoid induction of the terminal differentiation of a human squamous carcinoma. J Cell Physiol 142, 70-77. Vishwanatha JK, Chiang Y, Kumble KD, Hollingsworth MA, Pour PM (1993). Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis 14, 2575-2579. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, Sheng Z, Lau JW, Johnson PJ (1999). Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 154, 37-43. Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, Inoue H, Mori M, Sidransky D (2006). PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 66, 3921-3927. Zen Y, Adsay NV, Bardadin K, Colombari R, Ferrell L, Haga H, Hong SM, Hytiroglou P, Kloppel G, Lauwers GY, van Leeuwen DJ, Notohara K, Oshima K, Quaglia A, Sasaki M, Sessa F, Suriawinata A, Tsui W, Atomi Y, Nakanuma Y (2007). Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20, 701-709. Zen Y, Aishima S, Ajioka Y, Haratake J, Kage M, Kondo F, Nimura Y, Sakamoto M, Sasaki M, Shimamatsu K, Wakasa K, Park YN, Chen MF, Atomi Y, Nakanuma Y (2005). Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement. Pathol Int 55, 180-188. Zen Y, Fujii T, Itatsu K, Nakamura K, Minato H, Kasashima S, Kurumaya H, Katayanagi K, Kawashima A, Masuda S, Niwa H, Mitsui T, Asada Y, Miura S, Ohta T, Nakanuma Y (2006). Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology 44, 1333-1343. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26382 | - |
dc.description.abstract | Annexin家族是有核細胞結合鈣離子而欠缺EF hands的最大一類蛋白,在人類發現有12種不同的Annexin成員。Annexin A10 (ANXA10)有數項特別表徵,包括罕見表現,以及第三重複序列的codon 與四重核心重複序列第2型鈣離子結合區的不尋常丟失。我們之前的研究顯示ANXA10有一個序列較短的變異型,稱為ANXA10S,其結構與表現均非常獨特,僅表現於正常的肝細胞或肝細胞起源的腫瘤細胞。相較於ANXA10S,ANXA10可表現於胃,但在人類的癌症中所扮演的角色則完全不清楚。
本研究主要是觀察ANXA10在正常組織的分佈與各種癌症中的表現,探討其組織與腫瘤特異性,特別是診斷潛力,故著重在觀察由腹腔前腸源起的器官在癌化及遠處轉移的表現,藉此了解ANXA10在鑑別診斷上的價值。 關鍵字:胃癌,腹部前腸,膜聯蛋白,癌症,轉移 方法:本研究主要藉由使用特殊的抗ANXA10抗體,以免疫組織化學染色法(immunohistochemical stain, IHC),研究分析1,545個手術切除檢體。包括了胃癌(405例)、十二指腸癌(25例)、胰臟癌(73例)、總膽管癌(41例)、膽囊癌(29例)、肝癌(54例)、大腸癌(175例)、卵巢癌(35例)、其他癌症(284例),另有218個轉移檢體,128例良性腫瘤。 結果: (1) 在人類的成人或胚胎組織,ANXA10 '僅”大量表現在正常胃粘膜及十二指腸的Brunner氏腺體上皮的細胞核中。對於不同物種的老鼠、土撥鼠及新出生的迷你豬,ANXA10的表現在也嚴格局限於正常胃粘膜上皮。 (2) 對於癌症而言,ANXA10常表現在源起於腹腔前腸器官的腺癌。包括胃癌(57%, 231/405)、十二指腸癌(72%, 18/25)、胰臟癌(82%, 60/73)、總膽管癌(56%, 23/41)、膽囊癌(34%, 10/29)、肝內膽管癌(22%, 12/54)。 (3) 對於不是由腹腔前腸所發育而來的器官腫瘤,ANXA10也會表現在少數特定的腫瘤,包括卵巢的粘液性腫瘤,某些粘液性大腸癌及胃腸道的畸型瘤 (hamartomas) (4) 在387例原發性胃癌(primary GC)中,ANXA10表現主要是瀰漫型(diffuse type;74%,89/120)及混合型(mix type;75%,21/28),顯著高於腸型胃癌(intestinal type;18%,43/235),P<1x10-8。在早期胃癌中也有相同的發現,分別是瀰漫型82%(27/33)與腸型16% (6/37),P<1x10-8。但不論在何型的胃癌,ANXA10的表現與淋巴轉移及存活率並無明顯的相關性。 (5) 在34病患的殘存胃發生的原發性胃癌中,有83%主要的組織型態是腸型胃癌。在15例接受第二次胃半全切除手術的檢體中,有14例屬腸型胃癌(93%),其中6例有ANXA10表現(40%),同時較小的瘤腫(小於3公分)較常有ANXA的表現。P<0.05。 (6) 為了探討ANXA10的診斷價值,我們分析了肝及卵巢中的轉移性腫瘤,前三位分別是大腸直腸癌、胃癌及胰臟癌。相對於其中有87%大腸直腸癌及97%的胰臟癌轉移到肝臟,胃癌有較多的病例轉移到卵巢(54%), P<1x10-8。就女性患者而言,胃癌更明顯地轉移到卵巢(79%),顯著高於大腸直腸癌(31%)、胰臟癌(11%)及乳癌(27%),P值分別為 P<1x10-8,P<1x10-8及P <0.00003。 大部份轉移到卵巢的胃癌型態是瀰漫型/混合型(94%),而轉移到肝的胃癌則為腸型(100%),差異極端明顯,P<1x10-8。發生卵巢轉移的胃癌,其原發的胃癌及卵巢轉移病灶,ANXA10的表現率都很高,分別為83%及87%,都顯著高於轉移到肝臟的胃癌,分別為12%及12%,P值分別為P=0.000002 及 P=0.00002。 (7) 轉移到卵巢的兩個主要癌症是胃癌與大腸直腸癌,轉移性胃癌有87%的檢體有ANXA10表現,顯著高於轉移性大腸直腸癌(8%),P<1x10-8。 (8) 為了探討ANXA10在原發性與轉移性卵巢腫瘤的鑑別診斷價值,我們檢驗不同型態的卵巢原發性癌症,發現ANXA10常表現在粘液性的腫瘤(囊性腺瘤為73%及囊性腺癌為61%),而完全不表現在漿液性的腫瘤(腺瘤及腺癌),P值分別為 P=0.0034 及 P=0.0003。 (9) 在膽管癌(cholangiocarcinoma)的兩種前期病變(precursor lesion)中,有90%(60/67)的膽道上皮贅瘤(BilIN)有ANXA10表現,顯著高於導管內乳頭狀贅瘤(IPN-B)的56% (19/33)或是腺癌(adenocarcinoma)的48% (101/210),P<0.0006及P<1x10-8。 在284例膽道系統的癌症中,ANXA10較常表現在低位的膽道如胰臟或壺腹(ampulla of Vater),高於總膽管、膽囊及肝臟,比例分別為77% (76/99)比31% (40/127), P<1x10-8。 (10) 在肝門區或是發生在較大膽管之膽管癌的ANXA10表現,顯著高於肝內發生的週邊膽管癌(43%比9%, P<0.01),同時,分化較好的膽管癌的ANXA10表現(38%) 也會顯著高於分化較差者(3%),P=0.0008。 (11) 在73例胰臟的腺癌中有78%有ANXA10表現,這是所有腹腔前腸腫瘤中ANXA10表現最高者,可能與胰臟癌多為分化型有關,而分化較好的胰臟癌的ANXA10表現也確實顯著高於分化較差者(87%比50%,P=0.002)。ANXA10也常表現在胰臟的粘液性腫瘤(88%,7/8),而漿液性腫瘤則完全不表現(0%,0/13),P<0.0001。 結論: (1) ANXA10蛋白是一核蛋白且呈現組織與細胞特異性表現,僅表現於正常胃粘膜上皮的細胞,及十二指腸的Brunner氏腺體,其特異性表現與消化道胃粘膜的發生與性狀的維繫有絕對的關係。 (2) ANXA10在腫瘤的表現也呈現侷限性,由腹腔前腸發育而來的器官的腺癌常見ANXA10的表現,ANXA10罕見表現於其他組織器官,也不會表現於非簡單柱狀黏液細胞。故有胃黏膜上皮細胞特異的ANXA10表現時可視為腫瘤胃化生(metaplasia)與分化(differentiation) 的表徵。 (3) 胃癌的ANXA10表現與組織學型態有重要的相關性,主要表現在仍保留胃粘膜特性的瀰漫型及混合型,較不表現在腸型。此一結果與胃癌的組織發生學,及ANXA10與正常胃粘膜之相關性具一致性。不過在本研究中ANXA10的表現與否和胃癌的分期、淋巴轉移及預後並無顯著的相關性。 (4) 因良性胃疾而全胃切除之殘胃,二十餘年後發生的原發性胃癌,組織學型態主要是腸型。而在這些腸型的胃癌ANXA10多表現小於3公分的腫瘤中。 (5) 與其他主要癌症相比,胃癌更常轉移至卵巢。轉移到卵巢的胃癌組織學型態多為瀰漫型/混合型,不論是原發部位的胃癌或卵巢的轉移部位的組織大部份都有ANXA10的表現。反之,大部份轉移到肝臟的胃癌細胞組織學型態是腸型,不論是原發部位或轉移部位的胃癌組織都很少有ANXA10的表現。 (6) 與胃癌相比,轉移到卵巢的大腸直腸癌的ANXA10表現率極低,所以ANXA10表現可以用來做兩者的鑑別診斷。 (7) ANXA10在卵巢的良性或惡性之粘液性腫瘤表現率高,而漿液性腫瘤則罕見,ANXA10的表現有助鑑別診斷;在胰臟中亦有相同的現象,表示卵巢與胰臟粘液性腺瘤與腺癌都常見胃型化生或分化,有助於腫瘤發生的探討。但就卵巢的原發性與轉移性粘液性腺癌,單獨ANXA10的表現無法當成鑑別診斷的指標(marker)。 (8) ANXA10在BilIN、IPN-B及膽道的腺癌之表現率都相當高,表示在膽道系統的腺癌在早期癌化過程中,導管上皮細胞可能存在著普遍的胃型化生。 (9) 在肝臟的膽管癌中,位於肝門區且分化較好的膽管癌有最高的ANXA10表現率,而發生在肝週邊且分化較差的膽管癌ANXA10的表現率幾近於零,P<0.0004。顯示ANXA10與膽管癌的細胞分化及發生在肝中膽管位置有相關性。 (10)在胰臟的腺癌中,ANXA10的表現也與癌細胞的分化有相關性。 基於以上的發現,本研究提出以下的論點: (1) ANXA10是一個對胃粘膜上皮細胞具有專一性的指標,亦是細胞發生胃型化生的指標,常見表現於腹腔前腸來源器官腺癌,具有鑑別診斷的價值,也有助於特定部位之簡單立方上皮的良性或惡性腫瘤發生之探討。 (2) ANXA10對於卵巢發生的胃癌或大腸直腸癌轉移是一個有用的鑑別診斷指標。就胃癌而言,ANXA10的表現與否與胃癌組織型態及肝臟或卵巢轉移傾向有極高的相關性,此一特殊現象的意含與轉移機制和AXNA10表現的關聯性有待進一步探討。同時是否對其他器官的遠處轉移也可能具有適用性,特別是肺、腦與骨骼,亦有待研究。 | zh_TW |
dc.description.abstract | Annexins (ANXs) belong to the largest single category of eukaryotic calcium-binding proteins without EF hands, and there are 12 human annexin members. ANXA10 has several distinct features, including its rare expression, codon deletion in the conserved repeat 3, and an unusual ablation of the type II calcium-binding sites in tetrad core repeats 1, 3 and 4. Our previous study showed that ANXA10 had a novel, unique short isoform (ANXA10S), initially mistaken as ANXA10 (Liu et al., 2002), which was expressed exclusively in liver cells and neoplasms of liver cell lineage. ANXA10 was detected in the stomach but its tissue distribution and role in human cancer are not known. This study was aimed to determine the expression pattern of ANXA10 protein in normal tissues and human cancers, with emphasis on its expression in neoplasms of the organs derived from the abdominal foregut and the differential diagnostic value in the major metastases of the liver and ovary.
and to explore its diagnostic potential. Key words: annexin, gastric carcinoma, abdominal foregut, cancer, metastasis Methods: The immunohistochemical stain (IHC) using a specific rabbit polyclonal antibody against ANXA10 protein was applied to examine the tissue distribution of ANXA10 protein in various types of human neoplasms. A total of 1,545 surgical samples of primary and metastatic tumors were analyzed, including neoplasms of the stomach (405 cases), duodenum (25 cases), pancreas (73 cases); common bile ducts (41 cases); gallbladders (29 cases); liver (54 cases); colon (175 cases); ovary (35 cases); and other organs (284 cases), such as brain, thyroid, breast, oral cavity, pharynx, larynx, lung, esophagus, kidney, urinary bladder, testis, uterus and cervix, malignant lymphoma. The metastatic tumors of the liver and ovary included 218 of metastastic carcinomas and 128 benign tumors. Results: (1) ANXA10 protein was located in the nucleus and expressed diffusely but “exclusively” in the epithelial cells of normal fetal and adult human gastric mucosa and Brunner’s gland of the duodenum. (2) ANXA10 was detected in various types of adenocarcinomas of the organs derived from the abdominal foregut, including the stomach (57%, 231/405), duodenum (72%, 18/25), pancreas (82%, 60/73), common bile duct (56%, 23/41), gall bladder(34%, 10/29), cholangiocarcinoma (22%, 12/54). (3) In organs other than those derived from the abdominal foregut, ANXA10 protein was expressed in a limited number of neoplasms, including mucinous tumors of the ovary, some mucinous carcinomas of the colon, and hamartomas of the GI tract. (4) In 387 primary gastric cancer (GC), ANXA10 was detected most commonly in diffuse type GC (DGC; 74%, 89/120) and mixed type GC (MGC; 75%, 21/28), significantly higher than the intestinal type (IGC; 18%, 43/235), P<1x10-8. In early GC, the expression ANXA10 was also found more frequently in DGC/MGC than IGC, 82% versus 16%, P<1x10-8. (5) ANXA10 expression in gastric cancer did not correlate with lymph node metastasis and patient’s outcome in both DGC/MGC and IGC. (6) The major histological type of the 34 remnant GC were IGC (83%). In 15 resected advanced remnant GC cases, 93% were IGC, 6 were positive for ANXA10. ANXA10 protein was frequently expressed in the tumors which size is less than 3cm, P<0.05. (7) The great majority of the colorectal (87%) and pancreatic cancers (97%) metastasized to the liver, whereas the gastric carcinoma metastasized more frequently to the ovary than the colorectal and pancreatic cancers, P<1x10-8. In female patients, gastric carcinoma predominantly metastasized to the ovary (79%), significantly higher than those of the colorectal cancer (31%), pancreatic cancer (11%) and breast cancer (27%), P<1x10-8 , P<1x10-8 and P <0.00003, respectively.. The great majority of ovarian metastases of GCs were DGC/MGC (94%), whereas the liver metastases were predominantly IGC (100%), P<1x10-8. (8) As compared with metastatic colorectal cancer, ANXA10 was detected in 87% of 31 metastatic gastric cancers to the ovaries, but only in 8% of the 39 colorectal cancer, P<1x10-8 (9) ANXA10 protein was frequently expressed in mucinous tumors of the ovary tumors (73% in cystadenomas and 61% in cystadenocarcinomas), but in none of serous adenomas and adenocarcinomas, P=0.0034 and P=0.0003, respectively. (10) ANXA10 was detected in 90% (60/67) of the BilIN lesions, significantly higher than those of the IPN-B lesions (56%, or 19/33) and adenocarcinoma (48%, or 101/210), P<0.0006 and P<1x10-8, respectively. (11) A pair-wise analysis showed the differentiated cholangiocarcinoma at the hilar region had the highest positive rate for ANXA10 protein expression (63%), whereas the poorly differentiated cholangiocarcinomas of the liver parenchyma the lowest (0%), P<0.0004 (12) ANXA10 in pancreatic cancers was also expressed more frequently in well to moderately differentiated tumors than the poorly differentiated and undifferentiated tumors 87% versus 50%, P=0.0021. CONCLUSION: (1) ANXA10 was diffusely expressed in the nuclei of normal gastric mucosa, but absent or significantly decreased in the intestinal metaplasia. (2)ANXA10 was detected in adenocarcinomas of organs derived from the abdominal foregut. (3) ANXA10 might play a role in the maintenance of gastric differentiation. However, the ANXA10 expression did not correlate with tumor stage, lymph node metastasis and patient’s outcome. (4) Consistent with correlation with histological types of GC, the expression of ANXA10 in the remnant GC, in which the IGC predominated, was low. (5)The great majority of ovarian metastases of GCs were diffuse/mixed type GCs, and hence most of the primary GCs and ovarian metastases were positive for ANXA10 expression, whereas the liver metastases were predominantly IGCs, and mostly negative for ANAX10 expression. (6)ANXA10 protein expression, which was commonly positive in the metastatic gastric carcinoma to the ovaries, but rarely in the metastatic colorectal carcinoma (CRC), could serve as a diagnostic aid. (7) The most of the ovarian mucinous neoplasms showed gastric metaplasia or differentiation, and ANXA10 per se was not a differential diagnostic marker. (8) The high positive rate of ANXA10 expression in the BilIN, IPN-B, and biliary tree adenocarcinoma suggest that gastric metaplasia is an early and common event in the multistep malignant transformation of biliary adenocarcinoma. (9) The expression of ANXA10 in cholangiocarcinoma correlated with tumor cell differentiation and the level of intrahepatic bile duct. (10) In pancreas adenocarcinoma, the ANXA10 protein expression was also correlated with differentiated tumors. Based on the above findings, we suggest that: (1) ANXA10 is a specific biomarker for gastric mucosal epithelial cells, and a marker for gastric metaplasia or differentiation in benign and malignant neoplasms of the abdominal foregut and adenocarcinoma with simple columnar epithelium in several other anatomic sites. (2) With certain caution, ANXA10 is a useful differential biomarker for the metastatic gastric and colorectal cancers of the ovaries, and probably other distant metastases. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T07:08:17Z (GMT). No. of bitstreams: 1 ntu-97-R95444007-1.pdf: 3347619 bytes, checksum: feffee9d8ad9366447abbdd5f8383208 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 口試委員會審定書 ----------------------------------------------------------------------- I
中文摘要 ----------------------------------------------------------------------------------- II ABSTRACT -------------------------------------------------------------------------------- V 1. INTRODUCTION ---------------------------------------------------------------------- 1 1.1 Annexin family and ANXA10 ---------------------------------------------------- 1 1.1.1 Annexin family ---------------------------------------------------------------- 1 1.1.2 ANXA10 ------------------------------------------------------------------------ 1 1.1.3 Annexins and cancer ---------------------------------------------------------- 4 1.2 Cancers of the abdominal foregut derived organs ------------------------------ 5 1.2.1 Gastric carcinoma ------------------------------------------------------------- 6 1.2.1.1 Introduction---------------------------------------------------------------- 6 1.2.1.2 Histopathology and classification of gastric carcinoma ------------- 6 1.2.1.3 Remnant gastric cancer -------------------------------------------------- 8 1.2.2 Cholangiocarcinoma ---------------------------------------------------------- 9 1.2.2.1 Introduction --------------------------------------------------------------- 9 1.2.2.2 Histopathological classification of precursor lesions of cholangiocarcinoma ----------------------------------------------------- 10 1.3 Purposes of study ------------------------------------------------------------------- 11 2. MATERIAL and METHODS ---------------------------------------------------------- 13 2.1 Tissue sample ------------------------------------------------------------------------ 13 2.2 Generation of a rabbit polyclonal antibody against ANXA10 protein ------- 13 2.3 Immunohistochemistry ------------------------------------------------------------- 14 2.4 Exclusion criteria and control ----------------------------------------------------- 14 2.5 Scoring ------------------------------------------------------------------------------- 15 2.6 Statistical analysis ------------------------------------------------------------------ 15 3. RESULTS -------------------------------------------------------------------------------- 16 3.1 Distribution and expression of ANXA10 protein in fetal and adult tissues across the species ------------------------------------------------------------------- 16 3.1.1 Tissue- and cell type- restrictive nuclear expression of ANXA10 protein: a biomarker of gastric differentiation ---------------------------- 16 3.1.2 Loss of ANXA10 protein expression in intestinal metaplasia of the gastric muocsa and expression in the metaplastic duodenal mucosa --- 17 3.2. Restrictive expression of ANXA10 in human cancers ------------------------ 17 3.2.1 Expression of ANXA10 in human cancers of abdominal foregut derived organs ----------------------------------------------------------------- 17 3.2.2 Expression of ANXA10 in adenocarcinoma of other anatomic sites --- 18 3.2.3. Expression of ANXA10 in benign mucinous tumors and gastrointestinal hamartomas ------------------------------------------------- 18 3.3 ANXA10 Expression in Gastric Cancers ---------------------------------------- 19 3.3.1 Loss of ANXA10 expression in gastric carcinoma (GC) ----------------- 19 3.3.2 Preferential expression of ANXA10 in diffuse type gastric cancer regardless of tumor stage ----------------------------------------------------- 19 3.3.3 Lack of correlation of ANXA10 expression with lymphnode metastasis and survival ------------------------------------------------------- 20 3.4 ANXA10 protein expression in the remnant gastric cancer ------------------- 21 3.5 Differential expression of ANXA10 in metastatic gastric cancer to the ovaries and liver --------------------------------------------------------------------- 22 3.5.1 Differential metastasis of human cancers to the liver and ovary -------- 22 3.5.2 Predominant ovarian metastasis of gastric carcinoma in female patients -------------------------------------------------------------------------- 22 3.5.3 Different histological types of gastric carcinoma exhibit differential metastasis to the liver and ovary -------------------------------------------- 23 3.5.4 Close association of ANXA10 expression with histological types of metastatic gastric carcinoma to the liver and ovaries --------------------- 23 3.5.5 Expression of ANXA10 in benign and malignant mucinous tumors of the ovaries ---------------------------------------------------------------------- 24 3.5.6 ANXA10 as a differential biomarker for the metastatic gastric and colorectal cancers of the ovaries -------------------------------------------- 25 3.6 ANXA10 expression in the tumors of the biliary duct system ---------------- 25 3.6.1 Frequent expression of ANXA10 in the precursor lesions and carcinomas of the biliary system -------------------------------------------- 26 3.6.2 Correlation of ANXA10 expression with localization and differentiation of cholangiocarcinoma -------------------------------------- 27 3.7 Expression of ANXA10 in benign and malignant neoplasms of the pancreas ------------------------------------------------------------------------------ 27 3.7.1 Expression of ANXA10 in benign pancreatic neoplasms ---------------- 27 3.7.2 Expression of ANXA10 in malignant pancreatic neoplasms ------------- 28 4. DISCUSSION ---------------------------------------------------------------------------- 30 ANXA10 in tissue distribution ------------------------------------------------------- 30 ANXA10 expression is lost in gastric carcinoma and plays an important role in gastric differentiation ----------------------------------------------------------------- 33 ANXA10 expression is not correlated with tumor progressoion ------------------ 34 Role of ANXA10 in the differential diagnosis of primary and metastatic mucinous neoplasms of the ovary ----------------------------------------------------- 34 ANXA10 expression and billiary system --------------------------------------------- 36 5. TABLES and FIGURES ---------------------------------------------------------------- 38 Table 1. ANXA10 protein expression in normal tissues ---------------------------- 38 Table 2. ANXA10 protein expression in human cancers of various anatomic sites ------------------------------------------------------------------------------ 39 Table 3. ANXA10 protein expression in 387 resected, primary gastric cancers- 40 Table 4. ANXA10 expression in relation to lymph node metastasis in primary gastric cancer ------------------------------------------------------------------ 40 Table 5. ANXA10 expression and overall survival in primary gastric cancer --- 41 Table 6. Clinicopathological features of the 34 patients with primary gastric cancer of the remnant stomach ---------------------------------------------- 42 Table 7. ANXA10 expression in 15 resected remnant primary gastric cancers - 42 Table 8A. Frequency of metastatic cancers of the liver and ovaries -------------- 43 Table 8B. Frequency of metastatic cancers of the liver and ovaries in female patients ------------------------------------------------------------------------ 43 Table 9. Comparison of histology and ANXA10 expression in metastatic gastric carcinomas of the liver and ovaries -------------------------------- 44 Table 10. Comparison between the liver and ovarian metastasis of gastric cancer -------------------------------------------------------------------------- 44 Table 11. ANXA 10 protein expression in benign tumors of ovary ------------- 45 Table 12A. ANX10 protein expression in surgically resected biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasm of the biliary tree (IPN-B) ------------------------------------------------- 45 Table 12B. Correlation of BilIN, IPN-B and adenocarcinoma lesions with biliary lithiasis ------------------------------------------------------------- 46 Table 13. ANXA10 protein expression in relation to tumor grade of cholangiocarcinoma --------------------------------------------------------- 46 Table 14. Expression of ANXA10 in cholangiocarcinoma in relation to the precursor lesions, and the differentiation and location of tumor ------ 47 Table 15. Expression of ANXA10 in cholangiocarcinoma in relation to tumor location and differentiation ------------------------------------------------- 47 FIGRURES ---------------------------------------------------------------------------------- 48 Fig. 1. Western blot of ANXA10 protein in gastric mucosa ----------------------- 48 Fig. 2. Adult stomach with diffuse expression of ANXA10 protein -------------- 48 Fig. 3. Duodenal mucosa --------------------------------------------------------------- 49 Fig. 4. Mouse gastric mucosa at the gastroesophageal junction ------------------- 49 Fig. 5. Gastric mucosa of adult woodchuck ------------------------------------------ 50 Fig. 6. Gastric mucosa and pancreatic islets of newborn mini pig ---------------- 50 Fig. 7. Fetal stomach of gestation age of 25 weeks and 38 weeks ---------------- 51 Fig. 8. Intestinal type gastric cancer --------------------------------------------------- 51 Fig. 9. Intestinal type gastric cancer, poorly differentiated ------------------------ 52 Fig. 10. Diffuse type gastric cancer composed of classical signet-ring cells ---- 52 Fig. 11. Mixed type gastric cancer ---------------------------------------------------- 53 Fig. 12. ANXA10 expression and overall survival of gastric carcinoma -------- 54 Fig. 13. Overall survival curves for patients with ANXA10-positive and -negative intestinal type gastric adenocarcinoma ------------------------- 54 Fig. 14. ANXA10 expression and five-year survival in diffuse and mixed type gastric cancer ------------------------------------------------------------------ 55 Fig. 15. Poorly differentiated intestinal gastric cancer of the remnant stomach and cystically dilated glands. ------------------------------------------------ 56 Fig. 16. Early diffuse type gastric cancer of the remnant stomach. --------------- 56 Fig. 17. Remnant gastric cancer of diffuse type. ------------------------------------ 57 Fig. 18. Early gastric cancer of poorly differentiated intestinal type. ------------ 57 Fig. 19. Remnant gastric cancer of papillary type. ---------------------------------- 58 Fig. 20. Diffuse gastric cancer composed of signet-ring cells and ovarian metastasis. ---------------------------------------------------------------------- 58 Fig. 21. Cholangiocarcinoma. ---------------------------------------------------------- 59 Fig. 22. Cholangiocarcinoma. ---------------------------------------------------------- 59 Fig. 23. Serous microcystic adenoma of the pancreas. ----------------------------- 60 Fig. 24. Serous cystadenoma of the pancreas. --------------------------------------- 60 Fig. 25. Mucinous cystadenoma of the pancreas showing diffuse expression of ANXA10. ----------------------------------------------------------------------- 61 Fig. 26. Mucinous cystadenoma of pancreas with prominent goblet cells 62 Fig. 27. ANXA10 expression in a well-differentiated ductal carcinoma of the pancreas. ------------------------------------------------------------------------ 63 Fig. 28. ANXA10 expression in a well-differentiated ductal carcinoma of pancreas. ------------------------------------------------------------------------ 63 Fig. 29. Absence of ANXA10 protein expression in a poorly differentiated carcinoma of the pancreas. --------------------------------------------------- 64 6. REFERENCE ---------------------------------------------------------------------------- 65 | |
dc.language.iso | en | |
dc.title | Annexin A10蛋白表現於腹腔前腸腫瘤及遠處轉移之探討 | zh_TW |
dc.title | Annexin A10 Protein Expression in Neoplasms and Distant Metastases of Abdominal Foregut Organs | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李偉華,孫家楝,曾暉華,李伯皇,陳祈安 | |
dc.subject.keyword | 胃癌,腹部前腸,膜聯蛋白,癌症,轉移, | zh_TW |
dc.subject.keyword | annexin,gastric carcinoma,abdominal foregut,cancer,metastasis, | en |
dc.relation.page | 73 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-08-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 3.27 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。